RxDoctor Payments Data

Amitkumar Patel, MD

Gastroenterology · Moline, ILNPI 1598059826

Payments from drug & device makers

$1,609in general payments, 2019–2025

Across 80 payments — averaging $20.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$384
  • Johnson & Johnson$239
  • Phathom Pharmaceuticals, Inc.$158
  • Takeda Pharmaceuticals U.S.A., Inc.$119
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$113
  • Conmed Corporation$77
  • plus $519 from 14 others

What the payments were for

  • Food & beverage$1,50994%
  • Education$1006%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,609 in reported general payments places this provider in the 50th percentile of 787 gastroenterology providers in Illinois.

See all gastroenterology providers in Illinois

Medicare billing

Part B allowed, 2024
$509,614
Medicare patients
547
Services billed
13,971

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase15$91,811
CreonLipase/Protease/Amylase11$41,650
Mesalamine36$18,099
Omeprazole903$17,187
LinzessLinaclotide18$14,889
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C87$12,311
Sucralfate68$11,558
Pantoprazole Sodium370$7,891
Lansoprazole15$4,629
Dexlansoprazole DrDexlansoprazole13$2,566
Mesalamine ErMesalamine15$1,856
Esomeprazole Magnesium42$1,366
Famotidine113$1,315
Budesonide DrBudesonide15$1,032
CholestyramineCholestyramine (With Sugar)14$780

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aimmune Therapeutics, Inc.Zenpep$33$91,81115 claims
AbbVieCreon, Linzess$384$56,53929 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$113$12,31187 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 787 gastroenterology providers in Illinois.

Other gastroenterology in Moline

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →